Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.53 |
| ▸ | F10 | P00742 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicatechin Pentaacetate SCHEMBL14691288 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| Catechin Pentaacetate SCHEMBL719419 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| (+/-)-Pentaacetylcatechin SCHEMBL14701425 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL5367055 | 0.92 | CYP3A4 (0.84) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL5109161 | 0.90 | ALDH1A1 (0.81) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL4671149 | 0.90 | ALDH1A1 (0.81) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL23135645 | 0.88 | ABCB1 (0.84) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL6702376 | 0.87 | CYP3A4 (0.77) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL14701484 | 0.87 | CYP3A4 (0.77) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 | |
| SCHEMBL16838244 | 0.86 | ALDH1A1 (0.75) | ALDH1A1CYP3A4MAPK1SMN1; SMN2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | claimed |
| US-8669048-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2014-03-11 | — | — | US | claimed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | claimed |
| CN-102245180-A | Compositions and methods for the treatment of altered alpha-synuclein function | PARKINSON S INST | 2011-11-16 | — | — | CN | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | claimed |
| EP-1921076-A1 | systhesis of procyanidin B2 | Proteotech Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1317437-B1 | SYNTHESIS OF 4-ALPHA-ARYLEPICATECHINS | MARS INC (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1554270-A2 | ISOLATION, PURIFICATION AND SYNTHESIS OF PROCYANIDIN B2 AND USES THEREOF | Proteotech, Inc. (US) | 2005-07-20 | — | — | EP | claimed |
| WO-2004033448-A2 | ISOLATION, PURIFICATION AND SYNTHESIS OF PROCYANIDIN B2 AND USES THEREOF | PROTEOTECH, INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-6365757-B1 | CULTURING TISSUES OF TAXUS WALLICHIANIA; ISOLATION BY PARTITIONING THE CULTURE PRODUCT RESIDUE, OBTAINED BY POLAR SOLVENT EXTRACTION; DESOLVENTIZING BETWEEN WATER AND CHLORINATED SOLVENTS; EVAPORATION; CHROMOTOGRAPHY; ADSORPTION; | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-04-02 | — | — | US | claimed |
| US-20230190937-A1 | IRON COMPLEXES OF ESTERIFIED DERIVATIVES OF NATURAL PRODUCTS, AND METHODS OF USE | CORNELL UNIVERSITY | 2023-06-22 | — | — | US | disclosed |
| CN-115868608-A | Method for reducing peroxide value of fried diced chicken | 浙江百珍堂食品有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-10233422-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2019-03-19 | — | — | US | disclosed |
| US-4413004-A | FLAVYLIUM SALTS AS VASO-PROTECTIVE AGENTS | INVERNI DELLA BEFFA S.P.A. (IT) | 1983-11-01 | — | — | US | disclosed |
| US-4376781-A | FLAVYLIUM SALTS HAVING HYPOLIPEMIC ANTIINFLAMMATORY, VASO-PROTECTIVE, HYPOCHOLESTEROLEMIC AND HYPOGLYCEMIC ACTIVITY | INVERNI DELLA BEFFA S.P.A. (IT) | 1983-03-15 | — | — | US | disclosed |
| US-4258055-A | USE OF FLAVYLIUM SALTS AS CICATRIZING AGENTS | INVERNI DELLA BEFFA S.P.A. (IT) | 1981-03-24 | — | — | US | disclosed |
| US-4166861-A | ESTERS OF CATECHIN AND EPICATECHIN; ANTILIPEMIC, ANTICHOLESTEROL, HEPATOPROTECTIVE | INVERNI DELLA BEFFA S.P.A. (IT) | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ALDH1A1 2223/4885CYP3A4 4355/4885MAPK1 4284/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | ALDH1A1 2054/4885CYP3A4 4539/4885MAPK1 4343/4885 |
| US-20230190937-A1 | IRON COMPLEXES OF ESTERIFIED DERIVATIVES OF NATURAL PRODUCTS, AND METHODS OF USE | SLC40A1, TFRC, HAMP | ALDH1A1 652/4885CYP3A4 3267/4885MAPK1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.